JCM | Free Full-Text | PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers | HTML
PARP Inhibition: A New Approach To Cancer Therapy? Dr. Geert Kolvenbag - ppt download
A decade of clinical development of PARP inhibitors in perspective - Annals of Oncology
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a <i>BRCA</i>1/2 Mutation. - Abstract - Europe PMC
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications | Molecular Cancer | Full Text
Olaparib
Dual mechanism of action of PARPi. Notes: Olaparib inhibits parylation... | Download Scientific Diagram
AstraZeneca-Merck & Co.'s Lynparza gets EU approval in prostate cancer | S&P Global Market Intelligence
Olaparib - Wikipedia
Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer | Clinical Cancer Research
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
Role of PARP Inhibitors in BRCA-Related Malignancies
Nausea and Vomiting: Managing Side Effects From PARP Inhibitors
Frontiers | Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors | Oncology
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers | Clinical Cancer Research
Olaparib in the management of ovarian cancer | PGPM
The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib - Gynecologic Oncology
PARP inhibitors in cancer treatment | OncologyPRO
Opportunities for the repurposing of PARP inhibitors for the therapy of non‐oncological diseases - Berger - 2018 - British Journal of Pharmacology - Wiley Online Library
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer - ScienceDirect
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective (Review)
